Navigation Links
Quorum Review’s Mitchell Parrish Presents at Embracing Change: Clinical Research in the 21st Century

Seattle, WA (PRWEB) September 12, 2013

Quorum Review IRB, the industry leader in central IRB services, announces Mitchell E. Parrish, JD, CIP, as a presenter at the event Embracing Change: Clinical Research in the 21st Century. The event takes place September 21, 2013 at Arizona State University in Phoenix, AZ.

Mr. Parrish presents two topics at the event. His first presentation, “Regulatory Implications of Recruiting Clinical Trial Participants through Social Media,” takes place at 8:30 AM. The presentation covers the use of social media in recruiting research participants and provides the tools necessary to ensure compliance with regulations impacting the use of social media. Mr. Parrish also presents “Understanding Safety and Non-Safety Reporting Obligations in Clinical Trials,” which takes place at 3:00 PM. The presentation unravels the regulatory maze impacting the reporting of safety and non-safety information in clinical trials and simplifies required site and sponsor reporting obligations.

Mr. Parrish is a Regulatory Attorney for Quorum Review, where he provides legal counsel on regulatory issues and FDA requirements associated with research and development of medical products. Mr. Parrish is a member of the Regulatory Affairs Professionals Society, Public Responsibility in Medicine & Research, American Association of Corporate Counsel, and Washington State Bar Association. He is also a Certified IRB Professional (CIP) and guest lectures for the Masters of Science Program in Biomedical Regulatory Affairs at the University of Washington. Prior to Quorum, Mr. Parrish served as Regulatory Counsel for Western IRB and as a Regulatory Consultant for the National Cancer Institute.

Embracing Change: Clinical Research in the 21st Century is a one-day event sponsored by Arizona State University, Arizona Department of Health Services, Arizona Biomedical Research Commission, Banner Research Institute, Association of Clinical Research Professionals and Creighton University Health Sciences Continuing Education. Geared toward medical providers and research professionals, the event provides education on regulatory requirements for clinical research, the roles and responsibilities for research team members, the value of cultural sensitivity in clinical research and the importance of working with a diverse population.

For the latest on Quorum Review News and Events, visit

About Quorum Review IRB

Quorum Review is an independent institutional review board fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), and has been providing ethics review of human clinical research since 1992. Quorum oversees research in accordance with U.S. and Canadian human subject research protection regulations and guidelines set forth by the International Committee on Harmonisation (ICH), and principles of the Belmont Report.

Quorum’s best-in-class IRB services include 14 Board meetings each week plus expedited review, 24-hour site review turnaround, 36-hour amendment review turnaround, a secure web portal, and Smart Forms for online submissions. Quorum’s IRB service offerings include full study review in the US and Canada, a specialized Phase I team, and unique processes for post-approval and registry studies.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Quorum Review IRB and ConsentSolutions Form Strategic Alliance
2. Quorum Review IRB Board Chair Appointed to SACHRP
3. Bayer CropScience Presents on Bee Health and Stewardship at International Pollinator Conference
4. Clinovo Presents Its Paper ‘Cloud for Clinical Trials’ at Society for Clinical Data Management (SCDM) Conference 2013
5. Vet-Stem, Inc. Founder and CEO, Robert Harman, DVM, Presents at Prestigious Stem Cell Conference at Case Western Reserve University
6. Bend Research Presents Drug Delivery Advancements at Controlled Release Society Annual Meeting
7. Sorrento Therapeutics Presents Preclinical Data of its Fully Human Antibody Programs Targeting Anti-PD-L1 and Anti-PD-1 at the 8th Annual Next Generation Protein Therapeutics Summit
8. Frost & Sullivan Presents bitop AG with the 2013 New Product Innovation Award in the Extremolytes Therapeutics Market
9. BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment
10. SACHEM Presents ZeoGen™ Structure Directing Agents at the 17th Annual IZC in Moscow
11. AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
Post Your Comments:
(Date:11/25/2015)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... of Neurocrine Biosciences, will be presenting at the 27th ... York . .   ... minutes prior to the presentation to download or install ... be available on the website approximately one hour after ...
(Date:11/25/2015)... ... 25, 2015 , ... A long-standing partnership between the Academy ... been formalized with the signing of a Memorandum of Understanding. , AMA Executive ... Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA Headquarters ...
(Date:11/25/2015)... , November 25, 2015 ... Research Report is a professional and in-depth study ...      (Logo: ) , ... of the industry including definitions, classifications, applications and ... provided for the international markets including development trends, ...
(Date:11/24/2015)... LUMPUR, Malaysia , Nov. 24, 2015 /PRNewswire/ ... global contract research organisation (CRO) market. The trend ... result in lower margins but higher volume share ... increased capacity and scale, however, margins in the ... Research Organisation (CRO) Market ( ), ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
Breaking Biology News(10 mins):